Glibenclamide steady state plasma levels during concomitant vinpocetine administration in type II diabetic patients.
The influence of vinpocetine on glibenclamide steady state plasma levels was investigated in 18 patients suffering from type II diabetes and symptoms of dementia. During the study patients continued to follow their individual scheme of glibenclamide intake and 10 mg vinpocetine were given t.i.d. from day 2 to 5. Glibenclamid as well as glucose plasma levels were repeatedly determined on the first day of the trial and compared to those on the fifth day where patients had received additional vinpocetine medication for four days. Time point comparisons were employed to exclude clinically relevant changes of glibenclamide bioavailability and kinetics. The data of this trial show that vinpocetine does not interfere with the kinetics of glibenclamide. Thus, it can be concluded that the comedication with vinpocetine does not represent a potential risk for a possible drug interaction in case of antidiabetics treatment with glibenclamide.
Grandt
R
R
Department of Angiology and Geriatrics, Medical University of Lübeck, Fed. Rep. of Germany.
Braun
W
W
Schulz
H U
HU
Lührmann
B
B
Frercks
H J
HJ
D001786:Blood Glucose / Q000378:metabolism; D003704:Dementia / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D004347:Drug Interactions; D005260:Female; D005905:Glyburide / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D014748:Vinca Alkaloids / Q000009:adverse effects* / Q000627:therapeutic use
D001786:Blood Glucose; D014748:Vinca Alkaloids; C013983:vinpocetine; D005905:Glyburide